The Warm Autoimmune Hemolytic Anemia Waiha Treatment Market plays a crucial role in modern hematology by enabling more precise and effective treatment options. It supports the development of novel ...
Breakthrough Therapy status for rilzabrutinib in wAIHA addressed the lack of approved treatments for this rare and life-threatening condition.
Sanofi wins FDA Breakthrough Therapy and Japan Orphan designations for Wayrilz in wAIHA, backed by LUMINA data and a ...
FDA grants breakthrough tag to Sanofi's rilzabrutinib for warm autoimmune hemolytic anemia, addressing a critical unmet ...
Sanofi has received Breakthrough Therapy designation from the U.S. FDA and orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for rilzabrutinib (Wayrilz) in warm autoimmune ...
Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi ...
Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia ...
In this prospective cohort study, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was found to elicit a complete ...
Signs and symptoms of warm autoimmune hemolytic anemia (AIHA) vary from person to person. Some individuals may be asymptomatic, especially those who develop symptoms gradually over several weeks to ...
A diagnosis of warm autoimmune hemolytic anemia (AIHA) requires a comprehensive clinical assessment, thorough documentation of medical history, identification of relevant signs and symptoms, and ...
A single dose of intravenous (IV) iron dextran is the most cost-effective treatment for women with heavy menstrual bleeding and iron deficiency anemia (IDA), according to new research published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results